Insights - Actavis (ACT) continued its acquisition spree on Mondau morning with the purchase of Durata Therapeutics (DRTX) in a deal valued at $675 million. The Dublin based … Continue Reading
Read NowInsights - Sunesis Pharmaceuticals (SNSS) announced Monday much-anticipated results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin (trademark Qinprezo) and cytarabine in … Continue Reading
Read NowRecap - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset … Continue Reading
Read NowInsights - Salix Pharmaceuticals Ltd. (SLXP) announced the end of a $2.7 billion merger agreement with Cosmo Pharmaceuticals SpA (COPN), citing tougher U.S rules for overseas inversions. … Continue Reading
Read NowInsights - Just after the close on Tuesday the United States’ Centers for Disease Control and Prevention (CDC) confirmed the first infection of Ebola Zaire in a … Continue Reading
Read NowInsights - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset is compound … Continue Reading
Read NowInsights - Catalyst Pharmaceuticals’ (CPRX) Firdapse (amifampridine phosphate) hit both co-primary endpoints successfully in a phase 3 trial in Lamberton-Eaton myasthenic syndroms (LEMS), announced on Monday afternoon. The stock climbed 20% … Continue Reading
Read Now
